Novartis concedes defeat with Cosentyx in RA
This article was originally published in Scrip
Executive Summary
Novartis has dropped development of its first-in-class anti-IL17a product Cosentyx (secukinumab) in rheumatoid arthritis after disappointing Phase III data.